Mo. Rev. Stat. § 191.1820

Current with changes from the 2023 Legislative Session
Section 191.1820 - Citation of law - definitions
1. Sections 191.1820 to 191.1855 shall be known and may be cited as the "Missouri Parkinson's Disease Registry Act".
2. For purposes of sections 191.1820 to 191.1855, the following terms mean:
(1)"Advisory committee", the Parkinson's disease registry advisory committee established in section 191.1830 to assist in the development and implementation of the registry;
(2)"Medical university", the University of Missouri and any other medical research university in the state that enters into a memorandum of understanding with the University of Missouri if deemed appropriate by the University of Missouri;
(3)"Parkinson's disease", a chronic and progressive neurologic disorder that:
(a) Results from deficiency of the neurotransmitter dopamine as the consequence of specific degenerative changes in the area of the brain called the basal ganglia;
(b) Is characterized by tremor at rest, slow movements, muscle rigidity, stooped posture, and unsteady or shuffling gait; and
(c) Includes motor and nonmotor symptoms and side effects including, but not limited to, autonomic dysfunction, thinking and mood changes, and other physical changes;
(4)"Parkinsonism", any condition that causes a combination of the movement abnormalities observed in Parkinson's disease, such as tremor at rest, slow movement, muscle rigidity, impaired speech, or muscle stiffness, with symptoms often overlapping, and that may evolve from what appears to be Parkinson's disease. The term "parkinsonism" shall include, but not be limited to, multiple system atrophy, dementia with Lewy bodies, corticobasal degeneration, and progressive supranuclear palsy;
(5)"Registry", the registry established by the medical university in section 191.1825.

§ 191.1820, RSMo

Added by 2023 Mo. Laws, HB 402,s A, eff. 8/28/2023.